Parasite-specific aptamers as biosynthetic reagents and potential pharmaceuticals

Trends in Parasitology

Volumn 28, Issue 3, 2012, Pages 106-113

  Göringer, H Ulrich ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; APTAMER; CHLOROQUINE; DNA; ERYTHROCYTE MEMBRANE PROTEIN 1; HISTONE H2A; HISTONE H3; NUCLEIC ACID BINDING PROTEIN; RNA; VARIANT SURFACE GLYCOPROTEIN;

BINDING AFFINITY; BIOSENSOR; CELL ADHESION; CELL INTERACTION; CELL INVASION; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; HUMORAL IMMUNITY; HYDROGEN BOND; HYDROPHOBICITY; LEISHMANIA; LEISHMANIA INFANTUM; LEISHMANIA TROPICA; LEISHMANIASIS; LIMIT OF DETECTION; MOLECULAR INTERACTION; NONHUMAN; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; REVIEW; RNA SEQUENCE; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CONGOLENSE; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPARKINSON AGENTS; APTAMERS, NUCLEOTIDE; DIRECTED MOLECULAR EVOLUTION; DRUG DISCOVERY; PARASITES;

TRYPANOSOMA;

EID: 84857234848     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2011.12.005     Document Type: Review

References (75)

1. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
2. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
3. Gold L. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 1995, 270:13581-13584.
4. Caruthers M.H. Gene synthesis machines: DNA chemistry and its uses. Science 1985, 230:281-285.
5. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999, 45:1628-1650.
6. Dausse E., et al. Aptamers: a new class of oligonucleotides in the drug discovery pipeline?. Curr. Opin. Pharmacol. 2009, 9:602-607.
7. Meyer C., et al. Cell-specific aptamers as emerging therapeutics. J. Nucleic Acids 2011, 2011:904750.
8. Pieken W. Efficient process technologies for the preparation of oligonucleotides. Ciba Found. Symp. 1997, 209:218-222.
9. Eaton B.E., Pieken W.A. Ribonucleosides and RNA. Annu. Rev. Biochem. 1995, 64:837-863.
10. Brody E.N., Gold L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 2000, 74:5-13.
11. Mayer G. The chemical biology of aptamers. Angew. Chem. Int. Ed. Engl. 2009, 48:2672-2689.
12. Hesselberth J., et al. In vitro selection of nucleic acids for diagnostic applications. J. Biotechnol. 2000, 74:15-25.
13. Paige J.S., et al. RNA mimics of green fluorescent protein. Science 2011, 333:642-646.
14. Ng E.W., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132.
15. Fernandez V., Wahlgren M. Rosetting and autoagglutination in Plasmodium falciparum. Chem. Immunol. 2002, 80:163-187.
16. Barfod A., et al. In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1. Parasitol. Res. 2009, 105:1557-1566.
17. Weissbuch I., Leiserowitz L. Interplay between malaria, crystalline hemozoin formation, and antimalarial drug action and design. Chem. Rev. 2008, 108:4899-4914.
18. Niles J.C., et al. Inhibiting Plasmodium falciparum growth and heme detoxification pathway using heme-binding DNA aptamers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13266-13271.
19. Li Y., et al. Recognition of anionic porphyrins by DNA aptamers. Biochemistry 1996, 35:6911-6922.
20. Okazawa A., et al. In vitro selection of hematoporphyrin binding DNA aptamers. Bioorg. Med. Chem. Lett. 2000, 10:2653-2656.
21. Homann M., Göringer H.U. Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res. 1999, 27:2006-2014.
22. Cross G.A.M. Identification, purification and properties of clone-specific glycoprotein antigens constituting the surface coat of Trypanosoma brucei. Parasitology 1975, 71:393-417.
23. Homann M., et al. Uptake and intracellular transport of RNA aptamers in African trypanosomes suggest therapeutic 'piggy-back' approach. Bioorg. Med. Chem. 2001, 9:2571-2580.
24. Adler A., et al. Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb. Chem. High Throughput Screen 2008, 11:16-23.
25. Lorger M., et al. Targeting the variable surface of African trypanosomes using VSG-specific, serum-stable RNA aptamers. Eukaryot. Cell 2003, 2:84-94.
26. Taylor J.E., Rudenko G. Switching trypanosome coats: what's in the wardrobe?. Trends Genet. 2006, 22:614-620.
27. Schwede A., Carrington M. Bloodstream form trypanosome plasma membrane proteins: antigenic variation and invariant antigens. Parasitology 2010, 137:2029-2039.
28. Freymann D., et al. 2.9Å resolution structure of the N-terminal domain of a variant surface glycoprotein from Trypanosoma brucei. J. Mol. Biol. 1990, 216:141-160.
29. Pieken W.A., et al. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991, 253:314-317.
30. Rice-Ficht A.C., et al. Point mutations during generation of expression-linked extra copy of trypanosome surface glycoprotein gene. Nature 1982, 298:676-679.
31. Michiels F., et al. Gene activation and re-expression of a Trypanosoma brucei variant surface glycoprotein. EMBO J. 1983, 2:1185-1192.
32. Urakawa T., et al. The primary structure of Trypanosoma (Nannomonas) congolense variant surface glycoproteins. Exp. Parasitol. 1997, 85:215-224.
33. Homann M., et al. Serum-stable RNA aptamers to an invariant surface domain of live African trypanosomes. Comb. Chem. High Throughput Screen 2006, 9:491-499.
34. Ramos E., et al. A DNA aptamer population specifically detects Leishmania infantum H2A antigen. Lab. Invest. 2007, 87:409-416.
35. Ramos E., et al. In vitro selection of Leishmania infantum H3-binding ssDNA aptamers. Oligonucleotides 2010, 20:207-213.
36. Requena J.M., et al. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol. Today 2000, 16:246-250.
37. Moreno M., et al. Selection of aptamers against KMP-11 using colloidal gold during the SELEX process. Biochem. Biophys. Res. Commun. 2003, 308:214-218.
38. Matos D.C., et al. Kinetoplastid membrane protein-11 is present in promastigotes and amastigotes of Leishmania amazonensis and its surface expression increases during metacyclogenesis. Mem. Inst. Oswaldo Cruz 2010, 105:341-347.
39. Jardim A., et al. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J. Immunol. 1991, 147:3538-3544.
40. Russo D.M., et al. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J. Immunol. 1992, 148:202-207.
41. Basu R., et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005, 174:7160-7171.
42. Moreno M., et al. Aptasensor based on the selective electrodeposition of protein-linked gold nanoparticles on screen-printed electrodes. Analyst 2011, 136:1810-1815.
43. Sieber F., et al. Mitochondrial RNA import: from diversity of natural mechanisms to potential applications. Int. Rev. Cell Mol. Biol. 2011, 287:145-190.
44. Bhattacharyya S.N., et al. Mitochondrial RNA import in Leishmania tropica: aptamers homologous to multiple tRNA domains that interact cooperatively or antagonistically at the inner membrane. Mol. Cell. Biol. 2002, 22:4372-4382.
45. Giordano R., et al. Trypanosoma cruzi binds to laminin in a carbohydrate-independent way. Braz. J. Med. Biol. Res. 1994, 27:2315-2318.
46. Giordano R., et al. Cloning of a surface membrane glycoprotein specific for the infective form of Trypanosoma cruzi having adhesive properties to laminin. J. Biol. Chem. 1999, 274:3461-3468.
47. Ouaissi M.A., et al. Trypanosoma cruzi infection inhibited by peptides modeled from a fibronectin cell attachment domain. Science 1986, 234:603-607.
48. Herrera E.M., et al. Mediation of Trypanosoma cruzi invasion by heparan sulfate receptors on host cells and penetrin counter-receptors on the trypanosomes. Mol. Biochem. Parasitol. 1994, 65:73-83.
49. Lima A.P., et al. Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J. Biol. Chem. 2002, 277:5875-5881.
50. Magdesian M.H., et al. Infection by Trypanosoma cruzi. Identification of a parasite ligand and its host cell receptor. J. Biol. Chem. 2001, 276:19382-19389.
51. Ulrich H., et al. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J. Biol. Chem. 2002, 277:20756-20762.
52. Goncalves M.F., et al. Trypanosoma cruzi: shedding of surface antigens as membrane vesicles. Exp. Parasitol. 1991, 72:43-53.
53. Morris K.N., et al. High affinity ligands from in vitro selection: complex targets. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2902-2907.
54. Ulrich H., et al. RNA and DNA aptamers as potential tools to prevent cell adhesion in disease. Braz. J. Med. Biol. Res. 2001, 34:295-300.
55. Esposito C.L., et al. New insight into clinical development of nucleic acid aptamers. Discov. Med. 2011, 11:487-496.
56. Thiel K.W., Giangrande P.H. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009, 19:209-222.
57. Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin. Biol. Ther. 2007, 7:1021-1034.
58. Bock L.C., et al. Selection of single- stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355:564-566.
59. Griffin L.C., et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993, 81:3271-3276.
60. DeAnda A., et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. 1994, 58:344-350.
61. Ruckman J., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998, 273:20556-20567.
62. Ostendorf T., et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 2001, 12:909-918.
63. Drolet D.W., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 2000, 17:1503-1510.
64. Bittker J.A., et al. Recent advances in the in vitro evolution of nucleic acids. Curr. Opin. Chem. Biol. 2002, 6:367-374.
65. Cox J.C., et al. Automated RNA selection. Biotechnol. Prog. 1998, 14:845-850.
66. Brody E.N., et al. The use of aptamers in large arrays for molecular diagnostics. Mol. Diagn. 1999, 4:381-388.
67. Drolet D.W., et al. A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). Comb. Chem. High Throughput Screen 1999, 2:271-278.
68. Zimmermann B., et al. Monitoring genomic sequences during SELEX using high-throughput sequencing: neutral SELEX. PLoS ONE 2010, 5:e9169.
69. Hoon S., et al. Aptamer selection by high- throughput sequencing and informatic analysis. Biotechniques 2011, 51:413-416.
70. Cho M., et al. Quantitative selection of DNA aptamers through microfluidic selection and high- throughput sequencing. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15373-15378.
71. Lai Y.T., DeStefano J.J. A primer-free method that selects high-affinity single- stranded DNA aptamers using thermostable RNA ligase. Anal. Biochem. 2011, 414:246-253.
72. Berezovski M., et al. Non-SELEX selection of aptamers. J. Am. Chem. Soc. 2006, 128:1410-1411.
73. Green L.S., et al. Aptamers as reagents for high-throughput screening. Biotechniques 2001, 30:1094-1110.
74. Burgstaller P., et al. Aptamers as tools for target prioritization and lead identification. Drug Discov. Today 2002, 7:1221-1228.
75. White R.R., et al. Developing aptamers into therapeutics. J. Clin. Invest. 2000, 106:929-934.